Sanofi Pasteur, Sanofi’s vaccine division, recently announced that it has launched a Global Health Vaccine Center of Innovation (GHVCI) as part of its collaboration with the Infectious Disease Research Institute (IDRI), a nonprofit, global-health institute that specializes in creating new products for infectious diseases.
The new Seattle-based center is partially funded with a grant from the Bill & Melinda Gates Foundation. This agreement was proposed as a research and development alliance called a Vaccine Discovery Partnership.
"IDRI is a partner of choice as they are a world leader in the development and evaluation of adjuvant formulations, using a broad portfolio of adjuvants with different immune-stimulating properties," Jim Tartaglia, research and development vice president for new vaccine projects at Sanofi Pasteur, said. "The institute has a world-class staff and capabilities in immunology and (good manufacturing practice) production.”
The center is designed to create vaccine adjuvant and/or formulation platforms as well as a pipeline for vaccine candidates. The researchers at the center will find, evaluate and create these vaccines and platforms to address a variety of infectious diseases.
"There are a number of diseases that are of great global-health significance, where Sanofi Pasteur could significantly contribute," John Shiver, senior vice president for research and development at Sanofi Pasteur, said. "However, commercial realities provide a challenge to investment. The establishment of this Global Health Vaccines Center of Innovation represents a new opportunity -- operating within the open innovation R&D model -- to provide antigens, adjuvanted formulations, funding and expertise to allow development of needed vaccines."